Current Management and Future Options for Tardive Dyskinesia

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

New Horizons for SMA.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Why New Treatments for Schizophrenia Should Be on Your Radar

Applying Biosimilars in Hematologic Cancers

Unraveling Clinical Developments in NASH

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Relapsed/Refractory Follicular Lymphoma Conundrums

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

New Standards of Care in ALK-Translocated Advanced NSCLC

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Optimizing Management of Advanced Bladder Cancer

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Therapeutic Approaches to the Management of EDS in OSA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

CGRP Antibodies in Migraine

Insights Into the Spectrum of Tardive Dyskinesia

Impactful Data in TD That Can Guide Treatment Decisions

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Prioritizing Prevention of HPV-Related Disease

The Psychiatrist's Role in Tardive Dyskinesia

The ABCs of Diagnosing Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders.

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Presentation transcript:

Current Management and Future Options for Tardive Dyskinesia

This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the US, as well as data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Tardive Dyskinesia

Prevalence of TD Has Not Declined

Prevention of TD

Treatment Initiation for TD

Initial Steps in Treating TD

Resolution of TD With Antipsychotic Discontinuation

Switching Antipsychotic Agents

AAN Guidelines

Double-Blind Trials With Amantadine or Clonazepam for TD

Extract of Ginkgo Biloba

Tetrabenazine

VMAT2

Trials of Tetrabenazine for TD

Tetrabenazine Limitations

Valbenazine

Valbenazine for TD KINECT 3: Phase 3 Trial Design

Valbenazine for TD KINECT 3: Phase 3 Trial Results

Valbenazine for TD KINECT 3: Phase 3 Extension

Deutetrabenazine

ARM-TD Trial Design

ARM-TD Trial Results

AIM-TD

TD Remains a Problem

The Dopamine System and TD

Conclusions

Abbreviations

Abbreviations (cont)